Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)
ID: 353975Type: Posted
Overview

Buyer

Centers for Disease Control and Prevention - ERA (HHS-CDC-HHSCDCERA)

Award Range

$0 - $500K

Eligible Applicants

Unrestricted

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353975
Timeline
    Description

    The Centers for Disease Control and Prevention (CDC) is offering a federal grant opportunity aimed at identifying and evaluating potential risk factors for Amyotrophic Lateral Sclerosis (ALS). This initiative seeks investigator-initiated research proposals that focus on various factors, particularly those related to military service, contact sports, traumatic brain injury, neuroinflammation, and infectious agents, with three distinct funding options available to support different types of research. The total estimated program funding is $7.5 million, with individual awards ranging from $0 to $500,000, and the agency anticipates making approximately eight awards. Interested applicants must submit their proposals electronically by November 4, 2024, and can direct inquiries to Candis M. Hunter, PhD, at ncipc_erpo@cdc.gov.

    Point(s) of Contact
    ncipc_erpo@cdc.gov
    Files
    No associated files provided.
    Similar Opportunities
    Public Health Strategies to Address Alzheimer's Disease and Related Dementias: The National Healthy Brain Initiative, BOLD Public Health Centers of Excellence, and Public Health Adoption Accelerator
    Active
    Centers for Disease Control - NCCDPHP
    The Centers for Disease Control and Prevention (CDC) is forecasting a funding opportunity titled "Public Health Strategies to Address Alzheimer's Disease and Related Dementias," aimed at enhancing public health initiatives through cooperative agreements. This initiative seeks to support organizations in developing and implementing strategies that align with the National Healthy Brain Initiative Road Map, focusing on areas such as dementia risk reduction, early detection, and caregiver support. The funding opportunity is critical as Alzheimer's disease is a leading cause of death among older adults in the U.S., and the program aims to build evidence-based practices to improve brain health and support caregivers. Interested applicants can apply for one or more of the three components, with funding amounts ranging from $750,000 to $3 million, and must submit their applications by March 7, 2025. For further inquiries, contact Alisha Etheredge at BOLD@cdc.gov or call 770-488-7884.
    Developing and Disseminating Strategies to Build Sustainable Lupus Awareness, Knowledge, Skills, and Partnerships
    Active
    Centers for Disease Control - NCCDPHP
    The Centers for Disease Control and Prevention (CDC) is forecasting a cooperative agreement opportunity titled "Developing and Disseminating Strategies to Build Sustainable Lupus Awareness, Knowledge, Skills, and Partnerships." This initiative aims to address significant gaps in lupus awareness and care by supporting national organizations in reducing the time to diagnosis, improving care coordination, and enhancing self-management among lupus patients. The program is particularly focused on increasing healthcare provider education and promoting effective self-management tools for individuals affected by lupus, a systemic autoimmune disease that disproportionately impacts women, especially those from minority communities. The estimated total program funding is $17.5 million, with individual awards ranging from $1.4 million to $1.8 million, and applications are due by May 2, 2025. Interested applicants can reach out to Stephanie Hinton at 678-938-9722 or via email at qxk8@cdc.gov for further information.
    Increasing awareness and knowledge of Alpha-gal Syndrome in the United States
    Active
    Centers for Disease Control - NCEZID
    The Centers for Disease Control and Prevention (CDC) is forecasting a cooperative agreement opportunity aimed at increasing awareness and knowledge of Alpha-gal Syndrome (AGS) in the United States. The initiative seeks to enhance AGS surveillance, patient care, and public understanding through strategies that include public health tracking, targeted education for at-risk populations, and dissemination of knowledge among stakeholders. With an estimated total program funding of $2,250,000, the CDC anticipates awarding three grants, with individual awards ranging from $25,000 to $1,000,000. Interested applicants can reach out to Jeff Borchert at JBorchert@cdc.gov or by phone at 970-221-6494, with applications due by January 22, 2025, and awards expected to be announced by July 1, 2025.
    Epilepsy Incidence Among Children in the United States
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) has announced a Notice of Funding Opportunity (NOFO) titled "Epilepsy Incidence Among Children in the United States," aimed at estimating the incidence of epilepsy among U.S. children aged 0 to 17 and identifying disparities influenced by demographic factors and social determinants of health. The initiative seeks to conduct a comprehensive study utilizing nationwide datasets to provide insights into epilepsy incidence, risk factors, and incidence disparities, thereby informing public health policies and resource allocation. With a total funding amount of $1.6 million available for a cooperative agreement over four years, the anticipated award for the first budget year is $500,000. Interested applicants, including small businesses and various organizations, must submit their applications by January 23, 2025, with a letter of intent due by December 12, 2024. For further inquiries, applicants can contact Natalie Brown at nbrown3@cdc.gov.
    Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research targeting Amyotrophic Lateral Sclerosis (ALS) patients through expanded access (EA) protocols, specifically under the initiative titled "Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)." This initiative aims to solicit applications for scientific research projects that utilize investigational drugs for ALS patients who are not eligible for clinical trials, with a focus on intermediate patient populations to address significant treatment gaps in ALS care. NIH plans to allocate up to $35 million in fiscal year 2025 to fund 2-5 new awards, contingent upon the quality of applications received, with a submission deadline of January 25, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Creutzfeldt-Jakob Disease (CJD) Increasing Educational Support for CJD Families and the Nation
    Active
    Centers for Disease Control - NCEZID
    The Centers for Disease Control and Prevention (CDC) is forecasting a funding opportunity titled "Creutzfeldt-Jakob Disease (CJD) Increasing Educational Support for CJD Families and the Nation," aimed at enhancing educational resources for families affected by CJD and related prion diseases. The cooperative agreement seeks to provide timely information to families, public health service providers, and health professionals to improve monitoring and understanding of prion diseases, particularly in light of the ongoing chronic wasting disease (CWD) outbreak among deer and elk. Eligible applicants include states, political subdivisions, and nonprofit entities, with funding ranging from $75,000 to a maximum of $100,000, and an estimated total program funding of $500,000. Interested parties should note that applications must be submitted electronically by March 18, 2025, with awards expected to be announced by September 1, 2025; for further inquiries, contact Tracey Ponder at TPonder@cdc.gov or by phone at 404-639-0953.
    Improving well-being for individuals living with a blood disorder through evidence-based programs.
    Active
    Centers for Disease Control - NCBDDD
    The Centers for Disease Control - NCBDDD is offering a federal grant opportunity aimed at improving the well-being of individuals living with blood disorders through evidence-based programs. The initiative seeks to enhance the emotional, social, and physical health of affected individuals by promoting mental health literacy and adapting programs that build psychosocial skills, ultimately aiming to reduce morbidity and improve quality of life. With an estimated total program funding of $5,925,000, the agency plans to award four cooperative agreements, with individual awards ranging from $135,000 to $450,000. Interested applicants can reach out to Dr. Fiona Bethea at gvu0@cdc.gov or by phone at 404-639-4033, with applications due by May 15, 2025, and awards expected to be announced by September 1, 2025.
    Occupational Safety and Health Education and Research Centers (T42)
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is inviting grant applications for the Occupational Safety and Health Education and Research Centers (T42) program, aimed at enhancing occupational safety and health training. This initiative seeks to ensure a sufficient supply of qualified personnel to fulfill the mandates of the Occupational Safety and Health Act, with a focus on interdisciplinary training, research, and outreach in key disciplines such as industrial hygiene and occupational health nursing. With an estimated total program funding of $32 million, the CDC plans to award up to 18 grants, each ranging from $4.5 million to $9 million over a duration of 3 to 5 years. Interested applicants must submit their proposals electronically by October 26, 2028, and can direct inquiries to Dr. Elizabeth H. Maples at lbrowning@cdc.gov or by phone at 404-498-5014.
    Assessment and Evaluation of Emerging Health Conditions Relevant to the World Trade Center Health Program (U01)
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is forecasting a federal grant opportunity titled "Assessment and Evaluation of Emerging Health Conditions Relevant to the World Trade Center Health Program (U01)." This cooperative agreement aims to support research projects that investigate health conditions potentially related to the September 11, 2001, terrorist attacks, focusing on diagnosing and treating conditions that have emerged since the establishment of the WTC Health Program. The initiative is particularly interested in interdisciplinary collaborations that address health equity and the health burdens faced by vulnerable populations exposed to the 9/11 attacks. The estimated total program funding is $33 million, with an award ceiling of $550,000 and approximately 20 awards expected. Interested applicants can reach out to Dr. James Yiin at JYiin@cdc.gov or by phone at 513-841-4271, with applications due by October 28, 2025, and awards anticipated by June 26, 2026.
    Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity for clinical trials aimed at addressing unmet needs in rare neurodegenerative diseases through the Notice of Funding Opportunity (NOFO) RFA-FD-25-001. This initiative, mandated by the ACT for ALS Act, seeks to support trials that evaluate the efficacy and safety of products for new indications or changes in labeling, with the goal of increasing the number of approved treatments for these conditions affecting fewer than 200,000 individuals in the U.S. Eligible applicants include various organizations such as higher education institutions and non-profits, with funding amounts capped at $650,000 for standard applications and up to $900,000 for innovative approaches. Interested parties should note that applications will be accepted starting August 23, 2024, with letters of intent and full applications due by October 22, 2024. For further inquiries, applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov.